Exenatide vs Tirzepatide: What the Research Compares

Exenatide and tirzepatide are prescription medicines that act on incretin receptors. Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist available as a prescription product for type 2 diabetes. Tirzepatide is a prescription medicine that acts at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. This page summarises what the published literature compares between them and what it does not compare, and it deliberately avoids ranking the two or suggesting that either is suited to any particular person.

This page is for educational purposes only and is not medical advice; consult a licensed physician about whether any prescription medicine is appropriate, since every question about use, suitability, monitoring and dosing belongs with a prescribing clinician.

Head-to-Head Randomised Trials: What Exists

No randomised controlled trial comparing exenatide directly with tirzepatide appears in the verified literature set used for this page. There is no named head-to-head study with exenatide in one arm and tirzepatide in the other arm to summarise here, so no primary endpoint, population or result can be attributed to such a trial. Stating that plainly matters, because comparisons that circulate informally often blend findings from separate trials that enrolled different populations, used different endpoints and ran for different durations.

Where direct comparison is absent, the honest alternative is a side-by-side look at the separate evidence bases, including class-level analyses that pooled multiple incretin-based agents. Several of the publications cited below examined GLP-1 receptor agonists or GLP-1-based therapies as a group rather than isolating one molecule, and that pooling is itself a limitation readers should keep in view when reading across agents.

Class and Mechanism Side by Side

The clearest documented difference between the two molecules is receptor coverage. A 2022 review in Peptides examined GLP-1 and GIP receptor signalling in beta cells, including how the two receptor systems interact and how co-stimulation has been studied (PMID 35065096). That review provides the pharmacological background for why a single-receptor GLP-1 agonist and a dual GIP and GLP-1 receptor agent are described as distinct pharmacological categories rather than interchangeable members of one class.

Dose information is not reproduced on this page. The verified publications summarised here were reviews, meta-analyses and pharmacovigilance analyses rather than individual dose-ranging trial reports, so no dosing figures can be attributed to them, and dosing decisions sit with a prescribing clinician in any case.

The Separate Evidence Bases, Compared Side by Side

Body weight and body composition

A 2024 article in Diabetes, Obesity and Metabolism addressed GLP-1 receptor agonist-based agents and weight loss composition, focusing on what published data describe about the tissue composition of weight change and where gaps remain (PMID 39344838). Because the analysis addressed agents as a group, it does not resolve how exenatide and tirzepatide would compare if tested against each other in one trial.

A separate 2025 analysis in JAMA Surgery set obesity treatment with bariatric surgery against GLP-1 receptor agonists (PMID 40960852). That comparison placed the drug class alongside a surgical intervention rather than placing one incretin medicine alongside another, which again means it does not separate the two molecules discussed here.

Obstructive sleep apnoea

A 2026 network meta-analysis in Diabetes, Obesity and Metabolism compared continuous positive airway pressure with GLP-1 receptor agonists in obstructive sleep apnoea using randomised trial data (PMID 41725443). Network meta-analysis is the method researchers use when direct comparisons are missing, and the structure of that analysis illustrates how indirect evidence is assembled when head-to-head trials have not been run.

Liver outcomes

A 2025 systematic review and meta-analysis in The Journal of Clinical Endocrinology and Metabolism examined the efficacy of GLP-1-based therapies in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis (PMID 40489581). The study pooled GLP-1-based therapies rather than ranking individual agents against one another.

Psychiatric research interest

A 2025 article in Der Nervenarzt reviewed whether GLP-1 receptor agonists represent a pharmacological treatment option under investigation for psychiatric illnesses (PMID 40042613). The piece described an exploratory research area rather than established practice, and it did not isolate exenatide or tirzepatide for separate comparison.

Adverse Events: What Studies Report

Published safety literature for these medicines has mostly been written at the class level, which means reported events are frequently described for GLP-1 receptor agonists or GLP-1-based therapies collectively rather than attributed molecule by molecule.

Skin and hair

A 2024 review in Archives of Dermatological Research catalogued rare cutaneous adverse reactions associated with GLP-1 agonists as described in the published literature (PMID 38795152). A 2025 retrospective comparative analysis in the Journal of Drugs in Dermatology examined cutaneous adverse reactions across GLP-1 agonist therapies (PMID 40196945). A 2026 systematic review in Science Progress reviewed current evidence on GLP-1 therapies and hair loss and discussed implications for patient counselling (PMID 41998799).

Ear, nose and throat

A 2025 article in The Laryngoscope described otolaryngologic side effects associated with GLP-1 receptor agonists (PMID 39936458), an area less frequently discussed than gastrointestinal tolerability.

Metabolic and nutritional signals

A 2024 pharmacovigilance study in Frontiers in Pharmacology analysed metabolic and nutritional adverse events reported for GLP-1 receptor agonists using spontaneous reporting data (PMID 39040467). Pharmacovigilance databases collect reports that have not been verified as causal, so researchers treat such signals as hypothesis generating rather than as measured incidence rates.

Pregnancy

A 2025 review in the American Journal of Obstetrics and Gynecology examined GLP-1 receptor agonist use in pregnancy and the state of the published evidence in that setting (PMID 39181497). Questions about pregnancy, contraception and family planning while taking any prescription medicine belong with a treating clinician.

How to Read a Comparison With No Head-to-Head Trial

When two medicines have never been randomised against each other, several interpretive cautions apply, and the publications cited on this page illustrate each of them:

• Pooling hides differences. Reviews that grouped GLP-1-based therapies, such as the 2025 liver meta-analysis (PMID 40489581), reported results for a category, not for one molecule.
• Indirect methods are explicit about their limits. The 2026 obstructive sleep apnoea network meta-analysis assembled randomised trials into a network precisely because direct comparisons were incomplete (PMID 41725443).
• Different comparators answer different questions. Setting the drug class against bariatric surgery, as a 2025 analysis did (PMID 40960852), answers a question about treatment categories rather than about two peptides.
• Safety data sources differ in strength. Spontaneous report analyses (PMID 39040467) and retrospective chart reviews (PMID 40196945) carry different limitations than randomised trials.
• Mechanistic difference is not an outcome claim. The receptor review described GIP and GLP-1 signalling and co-stimulation in beta cells (PMID 35065096) without establishing clinical superiority of either approach.

What Remains Unanswered

The published record summarised here leaves open how exenatide and tirzepatide would perform if randomised against each other in a single population with a shared primary endpoint, how their adverse-event profiles separate when analysed molecule by molecule rather than as a class, and how long-term outcomes compare beyond the durations covered by the reviews cited above (PMID 39344838). Until such trials are published and indexed, any statement that one of these medicines outperforms the other is an inference rather than a measured result.

Related Reading

• Exenatide: research overview
• Tirzepatide: research overview

References

• GLP-1 and GIP receptor signaling in beta cells: a review of receptor interactions and co-stimulation (Peptides, 2022)
• Comparative effectiveness of continuous positive airway pressure and glucagon-like peptide-1 receptor agonists in obstructive sleep apnea: A network meta-analysis of randomised trials (Diabetes, Obesity & Metabolism, 2026)
• Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis (The Journal of Clinical Endocrinology and Metabolism, 2025)
• Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists (JAMA Surgery, 2025)
• Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: Filling the gaps (Diabetes, Obesity & Metabolism, 2024)
• Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses? (Der Nervenarzt, 2025)
• Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature (Archives of Dermatological Research, 2024)
• A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies (Journal of Drugs in Dermatology, 2025)
• GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling (Science Progress, 2026)
• Otolaryngologic Side Effects of GLP-1 Receptor Agonists (The Laryngoscope, 2025)
• Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events (Frontiers in Pharmacology, 2024)
• Glucagon-like peptide-1 receptor agonist use in pregnancy: a review (American Journal of Obstetrics and Gynecology, 2025)